Fingerprint
Dive into the research topics of 'Anti-CD20 Cell Therapies in Multiple Sclerosis—A Fixed Dosing Schedule for Ocrelizumab is Overkill'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Anti-CD20 Cell Therapies in Multiple Sclerosis—A Fixed Dosing Schedule for Ocrelizumab is Overkill
Research output: Contribution to journal › Article › peer-review
12
Scopus
citations